|
Shengyang 463 Diabetic Foot Trial |
|
|
|
|
Monday, 26 September 2005 |
From
November 2003 to March 2005, Shengyang 463 Hospital treated fifty-seven
patients
with diabetic foot for a study to investigate the clinical efficacy of
transplantation of autologous peripheral blood stem cells as treatment.
The results showed that prominent remission of pain was achieved in
forty-six patients three to fourteen days after transplantation,
forty-eight
patients had
improvement of cold foot symptoms in two to seven days, four patients
had
obvious
improvement in their foot ulcers in four to twelve weeks and increase
in the ankle-brachial
index (ABI) was found in seventeen patients. Digital subtraction
angiographic
scores (DSA) showed new collateral vessel formation in two
patients after eight weeks. No related complications or adverse effects
were observed so far. The conclusion was the autologous PBSC
transplantation might be a simple, safe and effective therapeutic
method for diabetic foot.
Click read more to see before and after pictures.
There were fifty seven patients in this group, thirty-one males and
stwenty six females ranging from forty-seven to eighty-two years
of age with an average age of sixty-five. Their duration of their
illness ranged from eight months to seven years. All the patients had
cold foot symptoms and pain in
their lower limbs. Forty-nine patients had intermittent claudication
and among
them, thirty-one patients had rest pain and thirty-three patients had
abnormal color in the skin on their foot. Among the seventeen patients
with toe and/or foot ulcer, six
patients had gangrene and four patients had infection. All fifty-seven
patients
suffered in their bilateral lower limb vessels. They have treated one
hundred fifty eight
patients ias of September
2005 and are welcoming foreign patients for treatment in Shen
Zhen.
This study was done in the Shengyang
Cell Treatment Center led by Dr. Yang Xiao Feng who has done hematology
research over thirty years and has published fifty papers and four books. The
center has fifty beds, twenty-five staff including nine doctors/professors and
thirteen nurses with three full time staff for the stem cell research
lab. After much research, the Cell Treatment Center started focusing on
clinical stem cell treatments in 2003. Other treatments they have been
giving include treating acute leukemia with CIK cells from umbilical
cord blood and treating thighbone caput putrescence with patients own
spinal cord stem cells among others. They have done another study on
the Hematopoietic Blood Stem Cell Transplantation treating femur head necrosis with 40 patients which China Stem Cell
News will try to publish on this site. Shengyang 463 hospital works in
collaboration with the Beike group. Contact China Stem Cell News if you want to get in contact with Shengyang Hospital for treatment. Slides of one case from the study: Stem Cell Injection Procedure Circulation in Left Foot Before Injection  Circulation in Left Foot After Injection  Circulation in Right Foot Before Injection  Circulation in Right Foot After Injection |
|
Last Updated ( Monday, 03 October 2005 )
|
